[Seite 155↓]

Literaturverzeichnis

1 Abdel Rahman, A.A., Khidr, S.H., Ahmed, S.M., Aboutaleb, A.E., Evaluation of chloramphenicol- β -cyclodextrin inclusion complex, Eur. J. Pharm. Biopharm. 37, 34-37 (1991)

2 Ahmed, I., Gokhale, R.D., Shah, M.V., Patton, T.F., Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea, J. Pharm. Sci. 76, 583-586 (1987)

3 Ahmed, I., Patton, T., Effect of pH and buffer on precorneal disposition and ocular penetration of pilocarpine in rabbits, Int. J. Pharm. 19, 215-227 (1984)

4 Ahmed, I., Patton, T.F., Importance of the noncorneal absorption route in topical ophthalmic drug delivery, Invest. Ophthalmol. Vis. Sci. 26, 584-587 (1985)

5 Akiyama, S., Yokoyama, T., Takano, T., Kobayashi, C., Kanai, A., Application of cyclosporin for corneal graft, Nippon Ganka Gakkai Zasshi 97, 378-382 (1993)

6 Allison, A.C., Almquist, S.J., Muller, C.D., In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, Transplant. Proc. 23 , Suppl. 2, 10-14 (1991)

7 Anaizi, N.H., Swenson, C.F., Dentinger, P.J., Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid, Am. J. Health-Syst. Pharm. 55, 926-929 (1998)

8 Ashton, P., Podder, S.K., Lee, V.H.L., Formulation influence on conjunctival penetration of four beta-blockers in the pigmented rabbit: a comparison with corneal penetration, Pharm. Res. 8, 1166-1174 (1991)

9 Ausschuss für Arzneispezialitäten , Europäischer Öffentlicher Beurteilungsbericht: Cellcept® , CPMP 767, Rev. 5 (2003)

10 Auterhoff, H., Knabe, J., Höltje, H.D., Lehrbuch der Pharmazeutischen Chemie, Wiss. Verlagsgesellschaft mbH, S. 512-524 (1994)

11 Babiole, M., Wilhelm, F., Schoch, C., In vitro corneal permeation of unoprostone isopropyl (UI) and its metabolism in the isolated pig eye, J. Ocular Pharmacol. Ther. 17, 159-172 (2001)

12 Bary, A.R., Tucker, I.G., Davies, N.M., Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone, Eur. J. Pharm. Biopharm. 50, 237-244 (2000)

13 Bauer, K.H., Frömming, K.-H., Führer, C. (Hrsg.), Lehrbuch der Pharmazeutischen Technologie, Georg Thieme Verlag, Stuttgart/New York, 4., durchgesehene Auflage, S. 172-173 (1993)

14 Bauer, K.H., Frömming, K-H., Führer, C. (Hrsg.), Lehrbuch der Pharmazeutischen Technologie, Wissenschaftliche Verlagsgesellschaft, Stuttgart/New York, 6. durch-gesehene und korrigierte Auflage, S. 180 (1999)


[Seite 156↓]

15 Belvisi, M.G., Wicks, S.L., Battram, C.H., Bottoms, S.E., Redford, J.E., Woodman, P., Brown, T.J., Webber, S.E., Foster, M.L., Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity, J. Immunol. 166, 1975-1982 (2001)

16 Benson, H., Alto, P., Permeability of the cornea to topically applied drugs, Arch. Ophthalmol. 91, 313-327 (1974)

17 Berndt, S.M., Entwicklung und Charakterisierung galenischer Formulierungen zur potentiellen nasalen Anwendung von Androstendion und Levodopa, Dissertation, Humboldt Universität zu Berlin (2000)

18 Bertelmann, E., Jaroszewski, J., Pleyer, U., Corneal allograft rejection: current understanding, 2. Clinical implications, Ophthalmologica 216, 2-12 (2002)

19 Bertelmann, E., Knapp, S., Rieck, P., Keipert, S., Hartmann, C., Pleyer, U., Transkornealer – parakornealer Penetrationsweg für lokal applizierte Pharmaka am Auge – Mycophenolat Mofetil als Modellsubstanz, Ophthalmologe 100, 696-701 (2003)

20 Bisrat, M., Nyström, C., Edman, P., Influence of dissolution rate of sparingly soluble drugs on corneal permeability in vitro, Int. J. Pharm. 63, 49-56 (1990)

21 Brechue, W.F., Maren, T.H., pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors, Invest. Ophthalmol. Vis. Sci. 34, 2581-2587 (1993)

22 Bron, A.M., Garcher, C.P., Sirbat, D., Allaire, C.M., Lablache-Combier, M.J., Trinquand, C.J., Comparison of two fixed beta blocker-pilocarpine combinations: The carteolol study group, Eur. J. Ophthalmol. 4, 351-356 (1997)

23 Bruchhausen, von F., Ebel, S., Frahm, A.W., Hackenthal, E., Hagers Handbuch, Band 9, Stoffe P-Z, Springer Verlag, Berlin (1993)

24 Bruchhausen, von F., Ebel, S., Frahm, A.W., Hackenthal, E., Hagers Handbuch, Band 7, Stoffe A-D, Springer Verlag, Berlin (1993)

25 Bruchhausen, von F., Ebel, S., Frahm, A.W., Hackenthal, E., Hagers Handbuch, Band 8, Stoffe E-O, Springer-Verlag, Berlin (1993)

26 Bucolo, C., Spadaro, A., Mangiafico, S., Pharmacological evaluation of a new timolol/pilocarpine formulation, Ophthalmic Res. 30, 101-106 (1998)

27 Burger, A., Wachter, H. (Hrsg.), Hunnius: Pharmazeutisches Wörterbuch, Walter de Gruyter, Berlin/New York, 7. völlig neubearbeitete und stark erweiterte Auflage, S. 1103 (1993)

28 Burger, A., Wachter, H. (Hrsg.), Hunnius: Pharmazeutisches Wörterbuch, Walter de Gruyter, Berlin/New York, 7. völlig neubearbeitete und stark erweiterte Auflage, S. 196 (1993)

29 Camber, O., An in vitro model for determination of drug permeability through the cornea, Acta Pharm. Suec. 22, 335-342 (1985)

30 Cappello, B., Carmignani, C., Iervolino, M., Immacolata La Rotonda, M., Fabrizio Saettone, M., Solubilization of tropicamide by hydroxypropyl-beta-cyclodextrin and water-soluble polymers: in vitro/in vivo studies, Int. J. Pharm. 213, 75-81 (2001)


[Seite 157↓]

31 Carney, L.G., Hill, R.M., Human tear buffering capacity, Arch. Ophthalmol. 97, 951-952 (1979)

32 Carney, L.G., Hill, R.M., Human tear pH/ Diurnal variations, Arch. Ophthalmol. 94, 821-824 (1976)

33 Chao. J., Li, J., Meng, D., Huang, S., Preparation and study on the solid inclusion complex of sparfloxacin with HP-beta-cyclodextrin, Spectrochim. Acta A. Mol Biomol. Spectrosc. 59, 705-711 (2003)

34 Cheeks, L., Kaswan, R.L., Green, K., Influence of vehicle and anterior chamber protein concentration on cyclosporin penetration through the isolated rabbit cornea, Curr. Eye Res. 11, 641-649 (1992)

35 Chrai, S.S., Patton, T.F., Mehta, A., Robinson, J.R., Lacrimal and instilled fluid dynamics in rabbit eyes, J. Pharm. Sci. 62, 1112-1121 (1973)

36 Ciba-Geigy AG, Division Pharma, Sicherheitsdatenblatt, Trasicor/WS (1994)

37 Coupland, S.E., Penfold, P.L., Bilson, F.A., Hydrolases of anterior segment tissues in the normal human, pig and rat eye: a comparative study, Graefe`s Arch. Clin. Exp. Ophthalmol. 232, 182-191 (1994)

38 Crosson, C.E., Klyce, S.D., Beuermann, R.W., Epithelial wound closure in the rabbit cornea, Invest. Ophthalmol. 27, 464-473 (1986)

39 Cyclolab, Products and Prices of Cyclodextrin complexes and derivatives, Budapest (1994)

40 Davies, N.M., Wang, G., Tucker, I.G., Evaluation of a hydrocortisone/hydroxy-propyl- β -cyclodextrin solution for ocular drug delivery, Int. J. Pharm. 156, 201-209 (1997)

41 Dibbern, H.W., UV- und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf (1985)

42 Dinnendahl, V., Fricke, U., Arzneistoffprofile: Basisinformation über arzneiliche Wirkstoffe, GOVI Verlag GmbH, Pharmazeutischer Verlag, Eschborn (1981)

43 Doane, M.G., Jensen, A.D., Dohlmann, C.H., Penetration routes of topically applied eye medication, Am J. Ophthalmol. 85, 383-386 (1978)

44 Dolder, R., Skinner, F.S. (Hrsg.), Biopharmazeutische Aspekte der Augenarzneizubereitungen, In: Ophthalmika: Pharmakologie, Biopharmazie und Galenik der Augenarzneimittel, Wiss. Verlagsgesellschaft mbH, Stuttgart, S. 354-368 (1990)

45 Dolder, R., Skinner, F.S. (Hrsg.), Codex der Arznei- und Hilfsstoffe, In: Ophthalmika: Pharmakologie, Biopharmazie und Galenik der Augenarzneimittel, Wiss. Verlagsgesellschaft mbH, Stuttgart, S. 274-284 (1990)

46 Donn, A., Maurice, D.M., Mills, N.L., Studies on the living cornea in vitro, Arch. Ophthalmol. 62, 741-747 (1959)

47 Doorne, van H., Interactions between cyclodextrins and ophthalmic drugs, Eur. J. Pharm. Biopharm. 39, 133-139 (1993)


[Seite 158↓]

48 Drago, F., Emmi, I., Marino, V., Effects of beta blockers association with pilocarpine on rabbit intraocular pressure and heart rate, Pharmacol. Res. 4, 299-302 (1997)

49 Duncker, G., Reichelt, J., Effects of the pharmaceutical cosolvent hydroxypropyl-beta-cyclodextrin on porcine corneal endothelium, Graefe`s Arch. Clin. Exp. Ophthalmol. 236, 380-389 (1998)

50 Ebel, S., Würzburger Skripten zur Analytik, Reihe: Statistik, Teil 3, Würzburg (1992)

51 Echezarreta-López, M., Vila-Jato, J.L., Torres-Labandeira, J.J., The effects of cyclodextrins on the incompatibility dexamethasone-polymyxin B in solution, In: Szejtli, J., Szente, L., Proceedings of the Eighth International Symposium on Cyclodextrins, Kluwer Academic Publishers, S. 457-460 (1996)

52 Ehlers, N., Morphology and histochemistry of the corneal epithelium of mammals, Acta anat. 75, 161-198 (1970)

53 Esclusa-Díaz, M.T., Pérez-Marcos, M.B., Vila-Jato, J.L., Torres-Labandeira, J.J., Improvement in the dissolution properties of ketoconazole through multicomponent β -cyclodextrin complexation, In: Szejtli, J., Szente, L., Proceedings of the Eighth International Symposium on Cyclodextrins, Kluwer Academic Publishers, 305-308 (1996)

54 Europäisches Arzneibuch, Deutscher Apotheker Verlag, Stuttgart – Govi-Verlag, Pharm. Verlag GmbH, Eschborn, 3. Ausgabe (1997)

55 Fachinformation für Ärzte und Apotheker, Rote Liste-Online (2004)

56 Fachinformation Timpilo® , Chibret (2001)

57 Fiedler, H.P., Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, Editio Canto Verlag, Aulendorf (1989)

58 Fischer, A., Untersuchung von Mycophenolatmofetil in verschiedenen Vehikel-systemen zur dermalen Anwendung, Diplomarbeit, Halle-Wittenberg (2000)

59 Flood, K.G., Reynolds, E.R., Snow, N.H., Characterization of inclusion complexes of betamethasone-related steroids with cyclodextrins using high-performance liquid chromatography, J. Chromatogr. A. 903, 49-65 (2000)

60 Fraunfelder, F.T., Ocular β -blockers and systemic effects, Arch. Int. Med. 146, 1073-1074 (1986)

61 Freedman, K.A., Klein, J.W., Beta-cyclodextrins enhance bioavailability of pilocarpine, Curr. Eye Res. 12, 641-647 (1993)

62 Freundenberg, K., Cramer, F., Plieninger, H., Inclusion compounds of physiologically active organic compounds, Patent No. 895, 769 (1953)

63 Fridriksdóttir, H., Loftsson, T., Stefánsson, E., Formulation and testing of methazolamide/cyclodextrin eye drop solutions, J. Control. Release 44, 95-99 (1997)

64 Frömming, K.-H., Gelder, T., Mehnert, W., Inclusion compound of β -cyclodextrin and vitamin A acetate, Acta Pharm. Technol. 34, 152-155 (1988)

65 Frömming, K.-H., Wedelich, V., Mehnert, W., Einschlussverbindungen von Cyclodextrinen mit Piperazin, Arch. Pharm. 320, 294-297 (1987)


[Seite 159↓]

66 Glaser, E., Surmann, P., Praktische Mathematik in der Pharmazie, Georg Thieme Verlag, Stuttgart, S. 198 ff. (1981)

67 Gondhowiardjo, T.D., Haeringen, van N.J., Hoekzema, R., Pels, L., Kijlstra, A., Detection of aldehyde dehydrogenase activity in human corneal extracts, Curr. Eye Res. 10, 1001-1007 (1991)

68 Granero, G., Longhi, M., Thermal analysis and spectroscopic characterization of interactions between a naphthoquinone derivative with HP-beta-CD or PVP, Pharm. Dev. Technol. 7, 381-390 (2002)

69 Grant, R.L., Acosta, D., Prolonged adverse effects of benzalconium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells, Fund. Appl. Toxicol. 33, 71-82 (1996)

70 Grass, G.M., Robinson, J.R., Mechanisms of corneal drug penetration II: Ultrastructural analysis of potential pathways for drug movement, J. Pharm. Sci. 77, 15-23 (1988)

71 Green, K.E., Kearse, C.E., Ocular penetration of topical Delta9-tetrahydro-cannabinol from rabbit corneal or cul-de-sac application site, Curr. Eye Res. 21, 566-570 (2000)

72 Grunenberg, P., Laicher, A., Validierung einer Methode zur Partikelgrößen-bestimmung mittels Laser-Streulicht-Analyse, Pharmazie 49, 585-589 (1994)

73 Gudmundsdóttir, E., Stefánsson, E., Bjarnadóttir, G., Sigurjónsdóttir, J.F., Gudmundsdóttir, G., Másson, M., Loftsson, T., Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension, Invest. Ophthalmol. Vis. Sci. 41, 3552-3554 (2000)

74 Haeringen, van N.J., Tränenflüssigkeit, In: Hockwin, O. (Hrsg.), Biochemie des Auges, Ferdinand Enke Verlag, Stuttgart, S.107 (1985)

75 Harre, M., Schering AG, Berlin, Persönliche Information

76 Hartmann, V., Keipert, S., Physiko-chemische in vitro- und in vivo-Charakterisierung von Polymeren zur okularen Anwendung, Pharmazie 55, 440-443 (2000)

77 Haße, A., Entwicklung, Charakterisierung und Strukturuntersuchungen von tensidhaltigen Mehrkomponentensystemen zur okularen Anwendung, Dissertation Humboldt Universität zu Berlin (1996)

78 Haße, A., Keipert, S., Development and characterization of microemulsions for ocular application, Eur. J. Pharm. Biopharm. 43, 195-197 (1997)

79 Hause, I.A., Glucocorticoide in der Nierentransplantation, Pharmazie in unserer Zeit 4, 335 (2003)

80 Higuchi, T., Conners, K., Phase solubility techniques, Adv. Anal. Chem. Instrum. 4, 117-212 (1965)

81 Higuchi, T., Connors, K.A., Advances in analytical chemistry and instrumentation, New York Interscience , New York, S. 128-131 (1965)


[Seite 160↓]

82 Hooijmaaijer, E., Brandl, M., Nelson, J., Lustig, D., Degradation products of mycophenolate mofetil in aqueous solution, Drug Develop. Ind. Pharm. 25, 361-365 (1999)

83 Huang, H.-S., Schoenwald, R.D., Lach, J.L., Corneal penetration behavior of beta-blocking agents II: assessment of barrier contributions, J. Pharm. Sci. 72, 1272-1286 (1983)

84 Hull, D.S., Hine, J.E., Edelhauser, H.F., Hyndiuk, R.A., Permeability of the isolated rabbit cornea to corticosteroids, Invest. Ophthalmol. 13, 457-459 (1974)

85 Hurvitz, L.M., Kaufman, P.L., Robin, A.L., Weinreb, R.N., Crawford, K., Shaw, B., New developments in the drug treatment of glaucoma, Drugs 41, 514-532 (1991)

86 Irie, T., Uekama, K., Pharmaceutical applications of cyclodextrins, III. Toxicological issues and safety evaluation, J. Pharm. Sci. 86, 147-162 (1997)

87 Jansen, T., Xhonneux, B., Mesens, J., Borgers, M., Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium, Lens Eye Toxic Res. 7, 459-468 (1990)

88 Jarho, P., Cyclodextrins in eye drop formulations: studies with pilocarpine prodrugs, anandamide and dipivefrine, Doctoral dissertation, University of Kuopio, Finland (1997)

89 Jarho, P., Järvinen, K., Urtti, A., Stella, V.J., Järvinen, T., The use of cyclodextrins in ophthalmic formulations of dipivefrin, Int. J. Pharm. 153, 225-233 (1997)

90 Jarho, P., Järvinen, K., Urtti, A., Stella, V.J., Järvinen, T., Modified β -cyclodextrin (SBE- β -CD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits, J. Pharm. Pharmacol. 48, 264-270 (1996)

91 Jarho, P., Urtti, A., Pate, D.W., Suhonen, P., Järvinen, T., Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl- β -cyclodextrin, Int. J. Pharm. 137, 209-217 (1996)

92 Järvinen, K., Järvinen, T., Thompson, O., Stella, V.J., The effect of a modified β -cyclodextrin, SBE- β -CD, on the aqueous stability and ocular absorption of pilocarpine, Curr. Eye Res. 13, 897-905 (1994)

93 Järvinen, T., Järvinen, K., Prodrugs for improved ocular drug delivery, Adv. Drug Delivery Rev. 19, 203-224 (1996)

94 Järvinen, T., Järvinen, K., Urtti, A., Thompson, D., Stella, V.J., Sulfobutyl-ether- β -cyclodextrin (SBE- β -CD) in eye drops improves the tolerability of a topically applied pilocarpine prodrug in rabbits, J. Ocular Pharmacol. Ther. 11, 95-106 (1995)

95 Jianbin, C., Liang, C., Hao, X., Donpin, M., Preparation and study on the solid inclusion complex of ciprofloxacin with beta-cyclodextrin, Spectrochim. Acta A. Mol. Biomol. Spectrosc. 58, 2809-2815 (2002)

96 Kanai, A., Alba, R.M., Takano, T., Kobayashi, C., Nakajima, A., Kurihara, K., Yokoyaina, T., Fukamni, M., The effect on the cornea of alpha-cyclodextrin vehicle for cyclodextrin eye drops, Transplant. Proc. 21, 3150-3152 (1989)


[Seite 161↓]

97 Kana, J.S., Hoffmann, F., Buchen, R., Krolik, A., Wiederholt, M., Rabbit corneal allograft survival following topical administration of cyclosporin A, Invest. Ophthalmol. Vis. Sci. 22 , 686-690 (1982)

98 Kaur, I.P., Smitha, R., Aggarwal, D., Kapil, M., Acetazolamide: future perspective in topical glaucoma therapeutics, Int. J. Pharm. 248, 1-14 (2002)

99 Kearse, E.C., Green, K., Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of Delta9-tetrahydrocannabinol, Curr. Eye Res. 20, 496-501 (2000)

100 Keipert, S., Ophthalmika: Etablierte Arzneiformen und neue Konzepte, In: Müller, R.H., Hildebrand, G.E., Pharmazeutische Technologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, S. 37-58 (1997)

101 Keipert, S., Fedder, J., Böhm, A., Hanke, B., Interactions between cyclodextrins and pilocarpine – as an example of a hydrophilic drug, Int. J. Pharm. 142, 153-163 (1996)

102 Keipert, S., Schulz, G., Mikroemulsionen auf Saccharoseesterbasis, Teil 1: In-vitro-Charakterisierung, Pharmazie 49, 195-197 (1994)

103 Keipert, S., Siebenbrodt, I., Antiglaukomatosahaltige Ophthalmika mit prolongierter Wirkung auf Basis makromolekularer Hilfsstoffe, Teil 3: Optimierte, tropfbare Rezepturen auf Polyacrylatbasis, Pharmazie 45, 596-599 (1990)

104 Keipert, S., Siebenbrodt, I., Lüders, F., Bornschein, M., Mikroemulsionen und ihre potentielle pharmazeutische Nutzung, Pharmazie 44, 433-444 (1989)

105 Keipert, S., Voigt, R., Wechselwirkungen zwischen makromolekularen Hilfsstoffen und Arzneistoffen, 1. Mitteilung: Assoziationstendenzen zwischen Polyvinylalkohol und Lokalanaesthetika, Pharmazie 30, 589-590 (1975)

106 Kondo, T., Irie, T., Uekama, K., Combination effects of α -cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits, Biol. Pharm. Bull. 19, 280-286 (1996)

107 Kristinsson, J.K., Fridriksdóttir, H., Thórisdóttir, S., Sigurdardóttir, A.M., Stefánsson, E., Loftsson, T., Dexamethasone-cyclodextrin-polymer cocomplexes in aqueous eye drops, Invest. Ophthalmol. Vis. Sci. 37, 1199-1203 (1996)

108 Kurz, H., β -Rezeptorenblocker, In: Ammon, H.P.T., Arzneimittelneben- und -wechselwirkungen , Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 3. völlig neu bearbeitete Auflage, S. 177 (1991)

109 Larkin, G., Lightman, S., Mycophenolate mofetil/ A useful immunosuppressive in inflammatory eye disease, Ophthalmology 106, 370-374 (1999)

110 Lee, V.H.L., Chang, S.C., Oshiro, C.M., Smith, R.E., Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation, Curr. Eye Res. 4, 1117-1125 (1985)

111 Lee, V.H.L., Iimoto, D.S., Takemoto, K.A., Subcellular distribution of esterases in the bovine eye, Curr. Eye Res. 2, 869-876 (1983)

112 Lee, V.H.L., Li, H., Prodrugs for improved ocular drug delivery, Adv. Drug Delivery Rev. 3, 1-38 (1989)


[Seite 162↓]

113 Lehmann, L., Keipert, S., Gloor, M., Effects of microemulsions on the stratum corneum and hydrocortisone penetration, Eur. J. Pharm. Biopharm. 52, 129-136 (2001)

114 Liaw, J., Robinson, J.R., The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers, Int. J. Pharm. 88, 125-140 (1992)

115 Liaw, J., Rojanasakul, Y., Robinson, J.R., The effect of drug charge density on corneal transport, Int. J. Pharm. 88, 111-124 (1992)

116 Liu, F.-Y., Kildsig, D.O., Mitra, A.K., Beta-cyclodextrin/steroid complexation: Effect of steroid structure equilibria, Pharm. Res. 7, 869-874 (1990)

117 Loftsson, T., Bodor, N., The effect of cyclodextrins on percutaneous transport of drugs, In: Schmidt, E.W., Maibach, H.I., Percutaneous penetration enhancers, CRC Press, Boca Raton, Florida, S. 335-342 (1995)

118 Loftsson, T., Brewster, M.E., Pharmaceutical application of cyclodextrins, 1. Drug solubilization and stabilization, J. Pharm. Sci. 85, 1017 (1996)

119 Loftsson, T., Fridriksdóttir, H., Stefánsson, E., Thorisdóttir, S., Gudmundsson, Ö., Sigthorsson, T., Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits, J. Pharm. Pharmacol. 46, 503-504 (1994)

120 Loftsson, T., Fridriksdóttir, H., Thorisdóttir, S., Stefánsson, E., Sigurdardóttir, A.M., Gudmundsson, Ö., Sigthorsson, T., 2-Hydroxypropyl-beta-cyclodextrin in topical carbonic anhydrase inhibitor formulations, Eur. J. Pharm. Sci. 1, 175-180 (1994)

121 Loftsson, T., Fridriksdóttir, H., Thorisdóttir, S., Stefánsson, E., The effect of hydroxypropylmethylcellulose on release of dexamethasone from aqueous 2-hydroxypropyl- β -cyclodextrin formulations, Int. J. Pharm. 104, 181-184 (1994)

122 Loftsson, T., Järvinen, T., Cyclodextrins in ophthalmic drug delivery, Adv. Drug Deliv. Rev. 36, 59-79 (1999)

123 Loftsson, T., Másson, M., Cyclodextrins in topical drug formulations: theory and practice, Int. J. Pharm. 225, 15-30 (2001)

124 Loftsson, T., Másson, M., Sigurjónsdóttir, J.F., Fridriksdóttir, H., Enhanced complexation efficacy of cyclodextrins, The 17th Pharmaceutical Technology Conference and Exhibition, Dublin (1998)

125 Loftsson, T., Másson, M., Stefánsson, E., The effects of cyclodextrins on drug availability in pharmaceutical formulations, The 10th Symposium on Cyclodextrins, Ann Arbor, Michigan (2000)

126 Loftsson, T., Matthiasson, K., Másson, M., The effects of organic salts on the cyclodextrin solubilization of drugs, Int. J. Pharm. 262, 101-107 (2003)

127 Loftsson, T., Stefánsson, E. , Effect of cyclodextrins on topical drug delivery to the eye, Drug Devel. Ind. Pharm. 23, 473-481 (1997)


[Seite 163↓]

128 Loftsson, T., Stefánsson, E., Fridriksdóttir, H., Thórisdóttir, S., Kristinsson, J.K., Gudmundsdóttir, G., Topical acetazolamide-HP- β -CD eye drop solution, The 7th International Symposium on Cyclodextrins, Tokyo (1994)

129 Loftsson, T., Stefánsson, E., Kristinsson, J.K., Fridriksdóttir, H., Sverisson, T., Gudmundsdóttir, G., Thórisdóttir, S., Topically effective acetazolamide eye-drop solution in man, Pharm. Sci. 2, 277-279 (1996)

130 Longwell, A., Birss, S., Keller, N., Moore, D., Effect of topically applied pilocarpine on tear film pH, J. Pharm Sci. 65, 1654-1657 (1976)

131 Ludwig, A., LJnIu, N., Van Ooteghem, M., Evaluation of viscous ophthalmic vehicles containing carbomer by slit lamp fluorophotometry in humans, Int. J. Pharm. 61, 15-25 (1990)

132 Ludwig, A., Van Ooteghem, M., The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans, Int. J. Pharm. 54, 95-102 (1989)

133 Maasz, J., Röntgendiffraktometrie in der Pharmazie, Untersuchungen zur quantitativen Auswertung und Anforderungen an Apparatur und Probe, Eberhard-Karls-Universität zu Tübingen, Dissertation (1986)

134 Maestrelli, F., Mura, P., Casini, A., Mincione, F., Scozzafava, A., Supuran, C.T., Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents, J. Pharm. Sci. 91, 2211-2219 (2002)

135 Mantel, N., Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother. Rep. 50, 163-170 (1966)

136 Martin, A.N., Physikalische Pharmazie/ Pharmazeutisch angewandte physikalisch-chemische Grundlagen, Hrsg. und vollständig überarbeitet von Leuenberger, H., Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 366 (2002)

137 Másson, M., Loftsson, T., Másson, G., Stefánsson, E., Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing, J. Control. Release 59, 107-118 (1999)

138 Mastman, G.L., Blades, E.J., Henderson, J.W., The total osmotic pressure of tears in normal and various pathological conditions, Arch. Ophthalmol. 65, 509 (1961)

139 Maurice, D.M., Mishima, S., Ocular pharmacokinetics, In: Sears, M.C., Handbook of Experimental Pharmacology, Springer Verlag, Berlin-Heidelberg, S. 69 (1984)

140 Mester, U., Lohmann, C., Pleyer, U., Steinkamp, G., Volcker, E., Kruger, H.PS., A comparison of two different formulations of diclofenac sodium 0,1% in the treatment of inflammation following cataract-intraocular lens surgery, Drugs R. D. 3, 143-151 (2002)

141 Metz, G., Mycophenolatmofetil, ein neuer Wirkstoff zur Immunsuppression, Pharmazeut. Zeitung 33, 36-42 (1996)

142 Mikkelson, T.J., Chrai, S.S., Robinson, J.R., Altered bioavailability of drugs in the eye due to drug-protein interaction, J. Pharm. Sci. 62, 1648-1653 (1973)

143 Mitra, A.K., Mikkelson, T.J., Mechanism of transcorneal permeation of pilocarpine, J. Pharm. Sci. 77, 771-775 (1988)


[Seite 164↓]

144 Müller, B.W., Müller, R.H., Bestimmung von Teilchen im submikroskopischen Bereich mit der Photonenkorrelationsspektroskopie, Pharm. Ind. 45, 1150-1153 (1983)

145 Munroe, W.P., Rindone, J.P., Kershner, R.M., Systemic side effects associated with the ophthalmic administration of timolol, Drug Int. Clin. Pharmacy 19, 85-89 (1985)

146 Mutschler, E., Schäfer-Korting, M., Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 7., völlig neu bearbeitete Auflage, S. 301 (1996)

147 Mutschler, E., Schäfer-Korting, M., Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie , Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 7., völlig neu bearbeitete Auflage, S. 288 ff. (1996)

148 Norn, M.S., Postmortal vital staining of the external eye, Acta Ophthalmol. 57, 296-304 (1979)

149 Ono, N., Arima, H., Hirayama, F., Uekama, K., A moderate interaction of maltosyl-alpha-cyclodextrin with Caco-2-cells in comparison with the parent cyclodextrin, Biol. Pharm. Bull 24, 395-402 (2001)

150 Palm, D., Erkrankungen und Schädigungen des Auges, In: Fülgraff, G., Palm, D. Pharmakotherapie/ Klinische Pharmakologie , Gustav Fischer Verlag, Stuttgart, 9., neubearbeitete Auflage, S. 361 (1995)

151Pate, D.W., Järvinen, K., Urtti, A., Jarho, P., Mette, F., Mahadevan, V., Järvinen, T., Effects of topical anandamides on intraocular pressure in normotensive rabbits, Life Sci. 58, 1849-1860 (1996)

152 Patton, T.F., Robinson, J.R., Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes, J. Pharm. Sci. 65, 1295-1301 (1976)

153 Patton, T.F., Robinson, J.R., Influence of topical anesthesia on tear dynamics and ocular drug bioavailability in albino rabbits, J. Pharm. Sci. 64, 267-271 (1975)

154 Perez-Martinez, J.I., Gines, J.M., Arias, M.J., Moyano, J.R., Morillo, E., Ruiz-Conde, A., Sanchez-Soto, P.J., Novak, C., Preparation and characterization of 2,4-D complexes with α -cyclodextrin, In: Szejtli, J. and Szente, L.: Proceedings of the Eighth International Symposium on Cyclodextrins, Kluwer Academic Publishers, S. 623-626 (1996)

155 Pergande, G., Keipert, S., Antiglaukomatosahaltige Ophthalmika mit prolongierter Wirkung auf Basis makromolekularer Hilfsstoffe, Teil 1: In vitro-Untersuchungen, Pharmazie 45, 582-586 (1990)

156 Pergande, G., Keipert, S., Klatt, A., Antiglaukomatosahaltige Ophthalmika mit prolongierter Wirkung auf Basis makromolekularer Hilfsstoffe, Teil 2: In vivo-Untersuchungen, Pharmazie 45, 587-591 (1990)

157 Pfau, B., Kruse, F.E., Rohrschneider, K., Zorn, M., Fiehn, W., Burk, R.O.W., Voelker, H.E., Comparison between local and systemic cyclosporine concerning the concentration in conjunctiva, aqueous humor and blood., Ophthalmologe 92, 833-839 (1995)


[Seite 165↓]

158 Pfister, R.R., Burstein, N., The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study, Invest. Ophthalmol. 15, 246-259 (1976)

159 Pleyer, U., Immunebiology and prevention of allograft reaction after keratoplasty, Aeolus Press, Buren, Niederlande, S. 22-23 (1996)

160 Pleyer, U., Untersuchungen zur Immunbiologie und Prävention der Allograftreaktion nach experimenteller Keratoplastik, Habilitationsschrift der Universität Tübingen (1993)

161 Pleyer, U., Dannowski, H., Volk, H.D., Ritter, T., Corneal allograft rejection: current understanding 1. Immmunobiology and basic mechanisms, Ophthalmologica 215, 254-262 (2001)

162 Pleyer, U., Liekfeld, A., Baatz, H., Hartmann, C., Entzündliche Augen-erkrankungen: Pharmakologische Modulation immunmediierter Erkrankungen des Auges, Klin. Monatsbl. Augenheilkd. 214, 160-170 (1999)

163 Pleyer, U., Sherif, Z., Corticoids in ophthalmology, Ernst Schering Res. Found Workshop 40, 65-81 (2002)

164 Pleyer, U., Yang, J., Knapp, S., Schäcke, H., Schmees, N., Orlic, N., Otasevic, L., De Ruyter, M., Ritter, T., Keipert, S., Effects of a selective steroid receptor agonist (SEGRA) on experimental keratoplasty, Graefe`s Arch. Clin. Exp. Ophthalmol. , Im Druck (2004)

165 Porst, H., Kny, L., Zur Stabilität von Pilocarpinhydrochlorid in Augentropfen, Pharmazie 40, 23-29 (1985)

166 Porstmann, A., De Ruijter, M., Sedláková, K., Knapp, S., Vogt, K., Pleyer, U., Effects of topically applied Mycophenolate Mofetil on endotoxin-induced Uveitis (EIU), EVER (European Association for Vision and Eye Research) Abstract 3375, Alicante, Spanien (2002)

167 Pose-Vilarnovo, B., Santana-Penín, L., Echezarreta-López, M., Pérez-Marcos, M.B., Vila-Jato, J.L., Torres-Labandeira, J.J., Interaction of diclofenac sodium with β - and hydroxypropyl- β -cyclodextrin in solution, S.T.P. Pharma Sciences 9, 231-236 (1999)

168 Prausnitz, M.R., Noonan, J.S., Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye, J. Pharm. Sci. 87, 1479-1488 (1998)

169 Raber, T., Alcon Pharma, Freiburg, Persönliche Information (2004)

170 Rajagopalan, N., Chen, S.C., Chow, W.S., A study of the inclusion complex of amphotericin B in the presence of γ -cyclodextrin, Int. J. Pharm. 29, 161-168 (1986)

171 Rajewski, R.A., Stella, V.J., Pharmaceutical applications of cyclodextrins, 2. In vivo drug delivery, J. Pharm. Sci. 85, 1142-1168 (1996)

172 Ramer, R.M., Gasset, A.R., Ocular penetration of pilocarpine: the effect of pH on the ocular penetration of pilocarpine, Ann. Ophthalmol. 7, 293-296 (1975)

173 Rauscher, K., Voigt, J., Wilke I., Wilke, K.-Th., Chemische Tabellen und Rechentafeln für die analytische Praxis, VEB, Deutscher Verlag für Grundstoffindustrie, Leipzig, 3., neu bearbeitete und erweiterte Auflage, S.141 (1965)


[Seite 166↓]

174 Ravinet, E., Mermoud, A., Brignoli, R., Four years later: a clinical update on latanoprost, Eur. J. Ophthalmol. 13, 162-175 (2003)

175 Redmund, T.M., Duke, E.J., Coles, W.H., Simson, J.A., Crouch, R.K., Localization of corneal superoxide dismutase by biochemical and histocytochemical techniques, Exp. Eye Res. 38, 369-78 (1984)

176 Reer, O., Bock, T.K., Müller, B.W., In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to commercial product voltaren ophtha, J. Pharm. Sci. 83, 1345-1349 (1994)

177 Reim, M., Augenheilkunde, Ferdinand Enke Verlag, Stuttgart, 3. Auflage, S. 8-23 (1990)

178 Reinhard, T., Reis, A., Kutkuhn, B., Godehardt, E., Spelsberg, H., Althaus, C., Sundmacher, R., Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial, Br. J. Ophthalmol. 83, 1268-1271 (1999)

179 Reis, A., Reinhard, T., Sundmacher, R., Althaus, C., Voisculescu, A., Kutkuhn, B., Mycophenolatmofetil (Cell Cept®) bei okulären immunologischen Störungen, Klin. Monatsbl. Augenheilkd. 213, 257-261 (1998)

180 Reis, A., Reinhard, T., Sundmacher, R., Braunstein, C., Godehardt, E., , Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine graft rejection model, Br. J. Ophthalmol. 82, 700-703 (1998)

181 Reis, A., Reinhard, T., Voisculescu, A., Kutkuhn, B., Godehardt, E., Spelsberg, H., Althaus, C., Sundmacher, R., Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial, Br. J. Ophthalmol. 83, 1268-1271 (1999)

182 Renz, M., Parenterals, Research and Development/Pharmaceutical Development, Schering AG, Berlin (2001)

183 Richman, J.B., Tang-Liu, D.D.-S., A corneal perfusion device for estimating ocular bioavailability in vitro, J. Pharm. Sci. 79, 153-157 (1990)

184 Richter, T., Keipert, S., In vitro permeation studies company bovine nasal mucosa, porcine cornea and artificial membrane: androstenedione in microemulsions and in its single components, Eur. J. of Pharm. and Biopharm., Im Druck (2004)

185 Robinson, J.C., Ocular Anatomy and Physiology relevant to ocular drug delivery, In: Mitra, A.K., Ophthalmic drug delivery systems, Marcel Decker, New York, S. 29-57 (1993)

186 Roche Produktinformation (2001)

187 Roth, H.J., Fenner, H. (Hrsg.), Pharmazeutische Chemie III, Arzneistoffe: Struktur – Bioreaktivität – Wirkungsbezogene Eigenschaften, Georg Thieme Verlag, Stuttgart/ New York, 2. überarbeitete Auflage, S. 334 (1994)

188 Roth, H.J., Fenner, H. (Hrsg.), Pharmazeutische Chemie III, Arzneistoffe: Struktur – Bioreaktivität – Wirkungsbezogene Eigenschaften, Deutscher Apothekerverlag, Stuttgart, 3. Auflage (2000)


[Seite 167↓]

189 Rücker, G., Neugebauer, M., Willems, G.G. (Hrsg.), IR-Spektroskopie, Anwendungen in der Pharmazie, In: Instrumentelle pharmazeutische Analytik, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2. überarbeitete und erweiterte Auflage, S. 118-136 (1992)

190 Rücker, G., Neugebauer, M., Willems, G.G. (Hrsg.), Hochleistungs-Flüssigkeitchromatographie, In: Instrumentelle pharmazeutische Analytik, Wissen-schaftliche Verlagsgesellschaft mbH, Stuttgart, 2. überarbeitete und erweiterte Auflage, S. 270 (1992)

191 Saari, K.M., Jyrkkiö, H., Seppa, H., Loftsson, T., Stefánsson, E., Acute and chronic postoperative inflammatory reactions after cataract extraction and intraocular lens implantation, Exerta Medica International Congress, 1158 (1998)

192 Sanghavi, N.M., Mayekar, R., Fruitwala, M., Inclusion complexes of Terfenadine-cyclodextrins, Drug Dev. Indust. Pharm. 21 , 375-381 (1995)

193 Sasamoto, Y., Hirose, S., Ohno, S., Onoe, K., Matsuda, H., Topical application of cyclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis, Ophthalmologica 203 , 118-125 (1991)

194 Sax, C.M., Salamon, C., Kays, W.T., Guo, J., Yu, F.X., Cuthbertson, R.A., Piatigorsky, J., Transketolase is a major protein in the mouse cornea, J. Biol. Chem. 271 , 68-74 (1996)

195 Schäcke, H., Döcke, W-D., Asadullah, K., Mechanisms involved in the side effects of glucocorticoids, Pharmacology & Therapeutics 96 , 23-43 (2002)

196 Schäcke, H., Hennekes, H., Schottelius, A., Jaroch, S., Lehmann, M., Schmees, N., Rehwinkel, H., Asadullah, K., SEGRAs: A Novel Class of Anti-inflammatory Compounds, Ernst Schering Res. Found Workshop, 357-371 (2002)

197 Schäcke, H., Schottelius, A., Döcke, W.D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., Asadullah, K., Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects, Proc. Natl. Acad. Sci. USA. 101 , 227-232 (2004)

198 Schmees, N., Schering AG, Berlin, Persönliche Information

199 Schmidt, G., Rheumatische Erkrankungen – Antiphlogistische Behandlung mit Glucocorticoiden, In: Fülgraff, G., Palm, D., Pharmakotherapie/ Klinische Pharmakologie, Gustav Fischer Verlag, Stuttgart, 9. neubearbeitete Auflage, S. 219-220 (1995)

200 Schoenwald, R.D., Huang, H.-S., Corneal penetration behavior of β -blocking agents, I: physicochemical factors, J. Pharm. Sci. 72 , 1266-1272 (1983)

201 Schoenwald, R.D., Ward, R., Relationship between steroid permeability across excited rabbit cornea and octanol-water partition coefficients, J. Pharm. Sci. 67 , 786-788 (1978)

202 Scholz, M., In vitro-Permeationsstudien von hydrophilen Arzneistoffen an okularen Geweben und Zellkulturen, Dissertation, Humboldt Universität zu Berlin (2003)

203 Scholz, M., Keipert, S., Pleyer, U., Mycophenolate mofetil for ocular application, ARVO Abstracts: Invest. Ophthalmol. Vis. Sci., 572 (2001)


[Seite 168↓]

204 Schönwald, R.D., Deshpade, G.S., Rethwisch, D.G., Barfknecht, C.F., Penetration into the anterior chamber via the conjunctival/scleral pathway, J. Ocular Pharm. Therap. 13 , 41-59 (1997)

205 Shaw, L.M., Sollinger, H.W., Halloran, P., Morris, R.E., Yatscoff, R.W., Ransom, J., Tsina, L., Leown, P., Holt, D.W., Lieberman, R., Jaklitsch, A., Potter, J., Mycophenolate mofetil: A report of the consensus panel, Ther. Drug Monit. 17 , 690-699 (1995)

206 Siebenbrodt, I., Keipert, S., Poloxamer-Systems as Potential Ophthalmics, II. Microemulsions, Eur. J. Pharm. 39 , 25-30 (1993)

207 Siefert, B., Einfluß von Cyclodextrin auf die Löslichkeit und okulare Verfügbarkeit von Pilocarpin-HCl bzw. Thalidomid/ Penetrations- und Permeationsstudien an isolierter Cornea, Dissertation, Humboldt Universität zu Berlin (1998)

208 Siefert, B., Keipert S., Influence of α -cyclodextrin and hydroxyalkylated β -cyclodextrin derivatives on the in-vitro corneal uptake and permeation of aqueous pilocarpine-HCl solutions, J. Pharm. Sci. 86 , 716-720 (1997)

209 Siefert, B., Pleyer, U., Müller, M., Hartmann, C., Keipert, S., Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide, J. Ocular Pharmacol. Ther. 15 , 429-438 (1999)

210 Sieg, J.W., Robinson, J.R., Vehicle effects on ocular drug bioavailability, II: evaluation of pilocarpine, J. Pharm. Sci. 66 , 1222-1228 (1977)

211 Siverman-Kitchin, J.E., Keltz-Pomeranz, M., Pak, G., Washnik, K., Shupack, J.L., Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses, J. Am. Acad. Dermatol. 37 , 445-449 (1997)

212 Stefánsson, E., Thórisdóttir, S., Gudmundsson, O.G., Loftsson, T., Fridriksdóttir, H., Kristinsson, J.K., 2-Hydroxypropyl- β -cyclodextrin in eye drops. Evaluation of artificial tear-drops in human patients, In: Szejtli, J. and Szente, L. (Hrsg.), Proceedings of the Eight International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht/Boston/London, S. 391-394 (1996)

213 Stegemann, S., Optimierung der oralen Bioverfügbarkeit/ Der Einsatz von lipophilen Drug Delivery Systemen für schwerlösliche Arzneistoffe, PZ Prisma 10 , 73-85 (2003)

214 Stella, V.J., Rajewski, R.A., Cyclodextrine: their future in drug formulation and delivery, Pharm. Res. 14 , 556-567 (1997)

215 Sugrue, M., Harris, A., Adamsons, I., Dorzolamide Hydrochloride: A topically active, carbonic anhydrase inhibitor for the treatment of glaucoma, Drugs of today 33 , 283-298 (1997)

216 Sugrue, M.F., The pharmacology of antiglaucoma drugs, Pharm. Ther. 43 , 91-138 (1989)

217 Suhonen, P., Järvinen, T., Lehmussaari, K., Reunamäki, T., Urtti, A., Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop, Pharm. Res. 12 , 529-533 (1995)

218 Suhonen, P., Järvinen, T., Peura, P., Urtti, A., Permeability of pilocarpine acid diesters across albino rabbit cornea in vitro, Int. J. Pharm. 74 , 221-228 (1991)


[Seite 169↓]

219 Szejtli, J., Properties of cyclodextrins as limiting factors, In: Cyclodextrin Technology, Kluwer Academic Publishers, Dordrecht/Boston/London, S. 291 (1988)

220 Szejtli, J., CDs and their inclusion complexes, Akadémiai Kiadó, Budapest, S. 32 (1982)

221 Szente, L., Kis, G.L., Schoch, C., Fetz, A., Szemán, J., Szejtli, J., Development of a diclofenac-Na/HP- γ -CD ophthalmic composition, The 10th International Symposium on Cyclodextrins, Ann Arbor, Michigan, USA (2000)

222 Takano, T., Kobayashi, C., Alba, R.M., Kanai, A., The immunosuppressive effects of 0,025% cyclosporin eye drops in alpha-cyclodextrin on rabbit corneal allografts, Nippon Ganka Gakkai Zasshi 96 , 834-840 (1992)

223 Teuscher, E., Biogene Arzneimittel, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 5. Auflage, S. 102 (1997)

224 The Pharmaceutical Codex, The Pharmaceutical Press, London, 11th Edition (1979)

225 Thoma, K., Vetter, O., Pharmaceutical Quality of Liposomes, Requirement for Applicability, In: Puisieux, F., Couvreur, P., Delattre, J., Devissaguet, J.-P., Liposomes, New systems and new trends in their applications, Editions de Santé, Paris (1995)

226 Tonjum, A.M., Permeability of horseradish peroxidase in the rabbit corneal epithelium, Acta Ophthalmol. 52 , 650-658 (1974)

227 Uekama, K., Kondo, T., Nakamura, K., Irie, T., Arakawa, K., Shibuya, M., Tanaka, J., Modification of rectal absorption of morphine from hollow-type suppositories with a combination of α -cyclodextrin and viscosity-enhancing polysaccharide, J. Pharm. Sci. 84 , 15-20 (1995)

228 Ullmann, Elektronenmikroskopie, In: Kerker, H., Ullmanns Enzyklopädie der technischen Chemie, Verlag Chemie, Weinheim, 606-607 (1980)

229 Usayapant, A., Karara, A.H., Narurkar, M.M., Effect of 2-hydroxypropyl- β -cyclodextrin on the ocular absorption of dexamethasone und dexamethasonacetate, Pharm. Res. 12 , 1495-1499 (1991)

230 Vainio-Jylhä, E., Vuori, M-L., Pyykkö, K., Huupponen, R., Plasma concentration of topically applied betaxolol in elderly glaucoma patients, J. Ocular Pharm. Therap. 17 , 207-213 (2001)

231 Visor, G.C., Drug design strategies for ocular therapeutics, Adv. Drug Delivery Rev. 14 , 269-279 (1994)

232 Voigt, R., Pharmazeutische Technologie , Ullstein Mosby, Berlin/Wiesbaden, 9. neubearbeitete Auflage (1995)

233 Voltaren Ophtha CD, Fachinformation des Arzneimittel-Kompendium der Schweiz, Supplement 3 (2003)

234 Wacker Chemie, Produktinformation (1998)

235 Wacker Chemie GmbH, EU-Sicherheitsdatenblatt (91/155/EWG) (1999)

236 Wacker-Chemie GmbH, EU-Sicherheitsdatenblatt (91/155/EWG) (1994)

237 Wacker-Chemie GmbH, EU-Sicherheitsdatenblatt (91/155/EWG) (1996)


[Seite 170↓]

238 Wang, W., Sasaki, H., Chien, D.S., Lee, V.H.L., Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration, Curr. Eye Res. 10 , 571-579 (1991)

239 Wang, W., Sasaki, H., Chien, D.-S., Lee, V.H.L., Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration, Curr. Eye Res. 10 , 571-579 (1991)

240 Watsky, M.A., Jablonski, M.M., Edelhauser, H.F., Comparison of conjunctival and corneal surface areas in rabbit and human, Curr. Eye Res. 7 , 483-486 (1988)

241 Wendorff, A., Keipert, S., Optimierte Verfügbarkeit von β -Rezeptorenblockern aus einem Mikroemulsionssystem zur okularen Anwendung, DPhG Berlin-Brandenburg (1999)

242 Wheeler, L.A., The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension, Eur. Pat. No. 0435 682 A3 (1991)

243 Wiesend, B., Die Bestimmung von Pilocarpin und seinen Zersetzungsprodukten mit einer neuen HPLC-Methode, Pharm. Ztg. 1 , 44-47 (1988)

244 www.charite.de/avt/klinik/ltx/übersichtimmun.html (2003)

245 www.glaukom.de/therapie.htm l, Die medikamentöse Glaukomtherapie im Überblick (2003)

246 Yamada, Y., Takayanagi, R., Tsuchiya, K., Ito, K., Ohtani, H., Sawada, Y., Iga, T., Assessment of systemic adverse reactions induced by ophthalmic β -adrenergic receptor antagonists, J. Ocular Pharm. Ther. 17 , 235-248 (2001)

247 Zadok, D., Geyer, O., Zadok, J., Lazar, M., Krakowski, D., Nemet, P., Combined timolol and pilocarpine vs pilocarpine and timolol alone in the treatment of glaucoma, Am. J. Ophthalmol. 6 , 728-731 (1994)

248 Zaki, I., Fitzgerald, P., Hardy, J.G., Wilson, C.G., A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man, J. Pharm. Pharmacol. 38 , 463-466 (1986)

249 Zierhut, M., Stübinger, N., Aboalchamat, W., Landenberger, H., Bialasiewicz, A.A., Engelmann, K., Immunsuppressive Therapie mit Mycophenolatmofetil (Cellcept®) in der Behandlung der Uveitis, Ophthalmologe 98 , 647-651 (2001)

250 Zimmermann, T.J., Topical ophthalmic beta blockers: a comparative review, J. Ocular Pharm. Therap. 9 , 373-384 (1993)

251 Zink, C. (Hrsg.), Pschyrembel/ Klinisches Wörterbuch, Walter de Gruyter, Berlin, 255., völlig überarbeitete und stark erweiterte Auflage (1986)

252 Zurdel, J., Aboalchamat, B., Zierhut, M., Stubiger, N., Bialasiewicz, A., Engelmann, K., Early clinical results with mycophenolate mofetil in immunosuppressive therapy of ocular pemphigoid, Klin. Monatsbl. Augenheilkd. 98 , 222-228 (2001)


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
10.11.2004